![]()
- Stocks Looking Past Europe for a New Driver of the Rally
- Greeks Strike Against Austerity, EU Demands More Cuts
- EU Agrees Rules for $700 Trillion Derivatives Market
- Barclays Warns May Miss Medium-Term Profit Goal
- Citigroup Takes $50 Million Loss in Lending Rate Probe
- In Europe, Stagnation as a Way of Life
- Will Romney Regret Opposing Michigan Auto Bailout?
- Oil Demand to Grow With 'Two Speed' Outlook: IEA
- The Secret Lives of Traders—Seeking the Next Hot Thing
MOST POPULAR
HOT ON FACEBOOK
Roche May Have to Boost Genentech Bid
Roche's $43.7 billion offer to buy Genentech may not be the last one, Birgit Kulhoff, pharmaceuticals analyst at Rahn & Bodmer told CNBC Monday.
Swiss-based pharmaceutical company Roche, which already owns 55.9 percent of Genentech [DNA
Loading...
()
], is offering $89 per share to buy up the remaining stake, a 9 percent premium to the biotech company's closing share price on Friday.
"I think for Roche this proposed deal at least at the current terms is positive, for Genentech I think they probably will not be too happy because it really gives rather low valuation to Genentech," Kulhoff told "Worldwide Exchange." "I think we might see higher bids in the end."
A combined entity would have a bigger marketing clout, would cooperate better in research and development and would lower costs, she said.
"In the end it could make sense, but of course that all depends on the price," Kulhoff said.
It will be very important for Roche to maintain the culture of research and development at Genentech and to keep the innovation there going, she added.
Consolidation might continue with pharmaceutical companies buying biotech firms, as the valuations of biotech companies are still reasonable, Kulhoff said.
"That could be the start of a bigger M&A wave," she added.




